Idhifa Approved for Some With Acute Myeloid Leukemia

TUESDAY, Aug. 1, 2017 — Idhifa (enasidenib) has been approved by the U.S. Food and Drug Administration to treat adults with a specific genetic mutation that leads to relapsed or refractory acute myeloid leukemia (AML).
The mutation in the IDH2 gene…
Source: Topamax